Related references
Note: Only part of the references are listed.Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus
Srita Chakka et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases
Peter Blomgren et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Expert Perspective: An Evidence-Based Approach to Refractory Cutaneous Lupus Erythematosus
Robert Borucki et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
Adriana Coricello et al.
MOLECULES (2020)
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
Robert Harrington et al.
JOURNAL OF INFLAMMATION RESEARCH (2020)
TREATMENT SATISFACTION, EXPECTATIONS, PATIENT PREFERENCES AND CHARACTERISTICS, INCLUDING DIGITAL HEALTH LITERACY (DHL), AND THE IMPACT OF SUBOPTIMAL DISEASE CONTROL IN A LARGE INTERNATIONAL COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA): THE SENSE STUDY
P. C. Taylor et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
BIIB059, A HUMANIZED MONOCLONAL ANTIBODY TARGETING BDCA2 ON PLASMACYTOID DENDRITIC CELLS (PDC), SHOWS DOSE-RELATED EFFICACY IN THE PHASE 2 LILAC STUDY IN PATIENTS (PTS) WITH ACTIVE CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
V. Werth et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
Richard Furie et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Hypersensitive IFN Responses in Lupus Keratinocytes Reveal Key Mechanistic Determinants in Cutaneous Lupus
Lam C. Tsoi et al.
JOURNAL OF IMMUNOLOGY (2019)
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
Mark C. Genovese et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Kata P. Szilveszter et al.
FRONTIERS IN IMMUNOLOGY (2019)
Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
Alessia Alunno et al.
CELLS (2019)
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial
Richard A. Furie et al.
LANCET RHEUMATOLOGY (2019)
Interferon pathway in SLE: one key to unlocking the mystery of the disease
Lars Ronnblom et al.
LUPUS SCIENCE & MEDICINE (2019)
Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa
Mrinal K. Sarkar et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Daniel J. Wallace et al.
LANCET (2018)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
Desiree van der Heijde et al.
LANCET (2018)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip Mease et al.
LANCET (2018)
Lupus community panel proposals for optimising clinical trials: 2018
Joan T. Merrill et al.
LUPUS SCIENCE & MEDICINE (2018)
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients
Christine Braegelmann et al.
EXPERIMENTAL DERMATOLOGY (2016)
Venous and Arterial Thrombotic Events in Systemic Lupus Erythematosus
Andrea Hinojosa-Azaola et al.
JOURNAL OF RHEUMATOLOGY (2016)
Differential gene expression analysis in CCLE lesions provides new insights regarding the genetics basis of skin vs. systemic disease
R. Dey-Rao et al.
GENOMICS (2014)
Efficacy and Safety of Abatacept in Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Treatment of Lupus Nephritis With Abatacept
Anca D. Askanase et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Quality of Life Differences Between Responders and Nonresponders in the Treatment of Cutaneous Lupus Erythematosus
Aileen Y. Chang et al.
JAMA DERMATOLOGY (2013)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Development of the CLASI as a Tool to Measure Disease Severity and Responsiveness to Therapy in Cutaneous Lupus Erythematosus
Rachel Klein et al.
ARCHIVES OF DERMATOLOGY (2011)
Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases
Omer N. Pamuk et al.
ARTHRITIS RESEARCH & THERAPY (2010)
The SYK tyrosine kinase: a crucial player in diverse biological functions
Attila Mocsai et al.
NATURE REVIEWS IMMUNOLOGY (2010)
The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus
J Albrecht et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
Share Paper
